Trevi Therapeutics IncNASDAQ:TRVI
- LAST PRICE3.7800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.5000/ 2
- Ask / Lots3.8300/ 8
- Open / Previous Close3.7000 / 3.7800
- Day Range
- 52 Week Range
- Volume303,075
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TRVI |
|---|---|---|
| 09:32 ET | 2925 | 3.7 |
| 09:39 ET | 1030 | 3.7 |
| 09:41 ET | 707 | 3.655 |
| 09:48 ET | 3400 | 3.69 |
| 09:50 ET | 2858 | 3.77 |
| 09:52 ET | 600 | 3.775 |
| 09:54 ET | 520 | 3.78 |
| 09:56 ET | 592 | 3.8 |
| 09:59 ET | 100 | 3.8 |
| 10:01 ET | 100 | 3.825 |
| 10:03 ET | 300 | 3.85 |
| 10:06 ET | 400 | 3.805 |
| 10:10 ET | 500 | 3.81 |
| 10:12 ET | 400 | 3.775 |
| 10:14 ET | 4088 | 3.68 |
| 10:15 ET | 2000 | 3.72 |
| 10:17 ET | 200 | 3.74 |
| 10:19 ET | 603 | 3.745 |
| 10:24 ET | 1150 | 3.8 |
| 10:37 ET | 3439 | 3.735 |
| 10:39 ET | 100 | 3.72 |
| 10:44 ET | 2300 | 3.72 |
| 10:46 ET | 511 | 3.75 |
| 10:48 ET | 434 | 3.78 |
| 10:50 ET | 633 | 3.79 |
| 10:51 ET | 1238 | 3.755 |
| 10:55 ET | 415 | 3.755 |
| 11:00 ET | 650 | 3.75 |
| 11:04 ET | 910 | 3.77 |
| 11:06 ET | 217 | 3.81 |
| 11:08 ET | 300 | 3.81 |
| 11:18 ET | 9805 | 3.7464 |
| 11:20 ET | 486 | 3.74 |
| 11:22 ET | 312 | 3.77 |
| 11:24 ET | 1345 | 3.755 |
| 11:26 ET | 400 | 3.76 |
| 11:27 ET | 100 | 3.76 |
| 11:29 ET | 1041 | 3.75 |
| 11:31 ET | 1344 | 3.75 |
| 11:33 ET | 400 | 3.76 |
| 11:38 ET | 405 | 3.76 |
| 11:40 ET | 300 | 3.78 |
| 11:42 ET | 427 | 3.76 |
| 11:44 ET | 1776 | 3.755 |
| 11:47 ET | 300 | 3.77 |
| 11:49 ET | 916 | 3.755 |
| 11:51 ET | 1429 | 3.75 |
| 11:54 ET | 6328 | 3.72 |
| 11:56 ET | 3150 | 3.74 |
| 11:58 ET | 1100 | 3.74 |
| 12:02 ET | 623 | 3.74 |
| 12:05 ET | 317 | 3.75 |
| 12:07 ET | 617 | 3.75 |
| 12:09 ET | 1200 | 3.755 |
| 12:12 ET | 100 | 3.75 |
| 12:14 ET | 631 | 3.76 |
| 12:16 ET | 1331 | 3.76 |
| 12:20 ET | 500 | 3.75 |
| 12:21 ET | 500 | 3.75 |
| 12:25 ET | 1071 | 3.75 |
| 12:27 ET | 500 | 3.75 |
| 12:30 ET | 522 | 3.765 |
| 12:32 ET | 400 | 3.75 |
| 12:34 ET | 300 | 3.75 |
| 12:36 ET | 600 | 3.75 |
| 12:38 ET | 621 | 3.7569 |
| 12:41 ET | 900 | 3.75 |
| 12:43 ET | 200 | 3.74 |
| 12:45 ET | 1412 | 3.75 |
| 12:48 ET | 2000 | 3.75 |
| 12:50 ET | 1100 | 3.75 |
| 12:52 ET | 1791 | 3.75 |
| 12:54 ET | 800 | 3.76 |
| 12:56 ET | 2400 | 3.75 |
| 12:57 ET | 400 | 3.75 |
| 12:59 ET | 400 | 3.75 |
| 01:01 ET | 1000 | 3.75 |
| 01:03 ET | 1946 | 3.74 |
| 01:06 ET | 400 | 3.735 |
| 01:10 ET | 1847 | 3.745 |
| 01:14 ET | 424 | 3.745 |
| 01:15 ET | 405 | 3.745 |
| 01:19 ET | 408 | 3.745 |
| 01:24 ET | 400 | 3.745 |
| 01:26 ET | 322 | 3.75 |
| 01:30 ET | 1031 | 3.75 |
| 01:32 ET | 100 | 3.75 |
| 01:33 ET | 524 | 3.75 |
| 01:37 ET | 720 | 3.75 |
| 01:39 ET | 1025 | 3.78 |
| 01:42 ET | 10498 | 3.71 |
| 01:46 ET | 200 | 3.735 |
| 01:48 ET | 319 | 3.735 |
| 01:50 ET | 100 | 3.735 |
| 01:51 ET | 200 | 3.735 |
| 01:53 ET | 940 | 3.72 |
| 01:55 ET | 300 | 3.72 |
| 01:57 ET | 2252 | 3.78 |
| 02:00 ET | 1064 | 3.775 |
| 02:02 ET | 1725 | 3.755 |
| 02:04 ET | 100 | 3.755 |
| 02:06 ET | 400 | 3.775 |
| 02:11 ET | 407 | 3.795 |
| 02:13 ET | 1349 | 3.8015 |
| 02:18 ET | 200 | 3.81 |
| 02:20 ET | 442 | 3.8 |
| 02:22 ET | 200 | 3.8 |
| 02:27 ET | 805 | 3.8 |
| 02:29 ET | 250 | 3.7999 |
| 02:33 ET | 200 | 3.795 |
| 02:36 ET | 417 | 3.805 |
| 02:45 ET | 200 | 3.81 |
| 02:47 ET | 200 | 3.81 |
| 02:51 ET | 100 | 3.808 |
| 02:56 ET | 700 | 3.82 |
| 03:00 ET | 100 | 3.82 |
| 03:05 ET | 100 | 3.82 |
| 03:12 ET | 2579 | 3.795 |
| 03:14 ET | 51235 | 3.52 |
| 03:16 ET | 13430 | 3.62 |
| 03:18 ET | 300 | 3.63 |
| 03:20 ET | 1900 | 3.64 |
| 03:21 ET | 100 | 3.64 |
| 03:23 ET | 618 | 3.67 |
| 03:25 ET | 621 | 3.7 |
| 03:27 ET | 919 | 3.7 |
| 03:30 ET | 200 | 3.685 |
| 03:32 ET | 1245 | 3.71 |
| 03:34 ET | 721 | 3.725 |
| 03:36 ET | 1104 | 3.765 |
| 03:38 ET | 1220 | 3.755 |
| 03:39 ET | 2401 | 3.765 |
| 03:41 ET | 2328 | 3.79 |
| 03:43 ET | 1500 | 3.81 |
| 03:45 ET | 2150 | 3.795 |
| 03:48 ET | 1247 | 3.8 |
| 03:50 ET | 10805 | 3.72 |
| 03:52 ET | 2937 | 3.755 |
| 03:54 ET | 4421 | 3.81 |
| 03:56 ET | 1652 | 3.81 |
| 03:57 ET | 36573 | 3.72 |
| 03:59 ET | 14962 | 3.78 |
Aug 11, 2022
BRIEF-Trevi Therapeutics - Data From Full Set Of Subjects In Completed Phase 2 Canal Trial In Chronic Cough In Ipf Expected In Q3 Of 2022, from 5:11PM ET on Thursday Aug 11, 2022 by Thomson Reuters
5:11PM ET on Thursday Aug 11, 2022 by Thomson Reuters-- Earnings Flash (TRVI) TREVI THERAPEUTICS Reports Q2 Loss $-0.14, from 4:21PM ET on Thursday Aug 11, 2022 by MT Newswires
4:21PM ET on Thursday Aug 11, 2022 by MT NewswiresTrevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update, from 4:05PM ET on Thursday Aug 11, 2022 by PR Newswire
4:05PM ET on Thursday Aug 11, 2022 by PR Newswire
Aug 9, 2022
Trevi Therapeutics to Present at Upcoming August Conferences, from 7:30AM ET on Tuesday Aug 09, 2022 by PR Newswire
7:30AM ET on Tuesday Aug 09, 2022 by PR Newswire
Aug 4, 2022
Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022, from 5:42PM ET on Thursday Aug 04, 2022 by PR Newswire
5:42PM ET on Thursday Aug 04, 2022 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Trevi Therapeutics Inc | 164.8M | -2.8x | --- |
Enzolytics Inc | 160.6M | -0.5x | --- |
TFF Pharmaceuticals Inc | 160.4M | -4.4x | --- |
89Bio Inc | 163.9M | -0.9x | --- |
Immunic Inc | 157.1M | -1.7x | --- |
Celcuity Inc | 156.9M | -4.0x | --- |
Company Information
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat neurologically mediated conditions. It is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Haduvio is an oral extended-release (ER) formulation of nalbuphine. It is conducting Phase IIb/3 clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It is also conducting Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as Phase II CANAL trial. It has also commenced Phase Ib trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics of Haduvio. Its Haduvio development programs include Active Chronic Pruritus Programs, Prurigo Nodularis Program, and Chronic Cough in Idiopathic Pulmonary Fibrosis Program.
Contact Information
- Headquarters
- 195 Church St Fl 14NEW HAVEN, CT, United States 06510-2009
- Phone
- 203-304-2499
- Fax
- 203-304-2434
Executives
- Chairman of the Board
- David Meeker
- President, Chief Executive Officer, Director
- Jennifer Good
- Co-Founder, Chief Medical Officer
- Thomas Sciascia
- Chief Financial Officer
- Lisa Delfini
- Chief Development Officer
- William Forbes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $164.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 38.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.34 |
Book Value | $0.60 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
